Synthetic Biology's Defense Dollars: Signals and Perceptions
By Dr. Filippa Lentzos,
PLOS Blogs
| 12. 24. 2015
Untitled Document
Synthetic biology is swimming in defense dollars. The most recent figures available on US trends in synthetic biology research funding indicate that two thirds of the $200 million invested in 2014 came from the Department of Defense or its research agency DARPA. While many scientists see military money as just another source of funding on par with NIH or NSF funding—after all, the majority of the funds are for basic science without security classification and publication restrictions—there are good reasons not to brush it off. One of these is the perception of the field to outsiders.
From an international security perspective, the extensive influx of military funding can be perceived as threatening to analysts in other countries following these developments. The US Department of Defense declared just over $655 million on national biodefence research in 2014. Synthetic biology research appears, therefore, to make up about a fifth of the biodefence budget. DARPA aims not only to develop radically new, game-changing technologies for national security in order to maintain US technological supremacy, it also aims to create technological surprise...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...